Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

55.77 +1.64 (+3.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 514,551
Open 54.76
Bid (Size) 55.69 (4)
Ask (Size) 55.78 (1)
Prev. Close 54.13
Today's Range 54.47 - 57.36
52wk Range 30.88 - 75.10
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily

Performance

YTD
-0.68%
-0.68%
1 Month
+9.83%
+9.83%
3 Month
-8.12%
-8.12%
6 Month
+2.97%
+2.97%
1 Year
+64.51%
+64.51%

More News

Read More
The Latest Analyst Ratings For Arcellx
Via Benzinga
Expert Ratings For Arcellx
Via Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
Analyst Expectations For Arcellx's Future
Via Benzinga
Peering Into Arcellx's Recent Short Interest
Via Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
Via Benzinga
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
Via Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Arcellx, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Arcellx Provides First Quarter 2024 Financial Results
From Arcellx, Inc.
Via Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Via InvestorPlace
Arcellx to Participate in Two Upcoming Investor Conferences
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Arcellx, Inc.
Via Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
Via InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
Via Talk Markets
Topics Stocks
Exposures US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Via InvestorPlace
Exposures Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Via Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
Via InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.